Controlled-Release Biodegradable Implants for OSCC Chemoprevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for oral squamous cell carcinoma (OSCC) are limited by high toxicity, poor efficacy due to signaling redundancies, and lack of effective inhibitors for Stat3 activation, leading to recurrent and aggressive cancers.
Innovation Solution
Development of controlled-release pharmaceutical dosage forms using biodegradable polymers like poly(lactic-co-glycolic acid) combined with anti-interleukin 6 agents, synthetic vitamin A analogues, and estradiol metabolites, such as tocilizumab, fenretinide, and 2-methoxyestradiol, for localized delivery to prevent cancer recurrence and progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy and radiation are used to treat OSCC, then tumor growth is inhibited, but systemic toxicity increases and treatment efficacy is limited by signaling redundancies
Solution Approach 1:
The invention divides the treatment approach into multiple components: surgical resection followed by localized controlled-release implants containing multiple therapeutic agents (anti-IL-6 agents, vitamin A analogues, estradiol metabolites). This segmentation allows targeted delivery to the tumor bed while minimizing systemic exposure, thereby reducing toxicity while maintaining efficacy.
Solution Approach 2:
The patent implements local quality by using controlled-release formulations that deliver therapeutic agents directly to the tumor bed site. The biodegradable polymer matrix provides localized sustained-release of multiple agents at the specific treatment site, achieving high local concentration while maintaining low systemic levels, thus resolving the toxicity-efficacy contradiction.
2Duration of action of moving object
If conventional chemotherapy agents are administered, then some tumor growth inhibition is achieved, but the treatment duration is limited by drug resistance and signaling redundancies
Solution Approach 1:
The invention merges multiple therapeutic agents with complementary mechanisms of action into a single controlled-release formulation. The combination of anti-IL-6 agents (blocking the IL-6/Stat3 pathway), vitamin A analogues (inducing differentiation and apoptosis), and estradiol metabolites (inhibiting angiogenesis and proliferation) creates a multi-targeted approach that overcomes signaling redundancies and extends effective treatment duration while preventing resistance.
Solution Approach 2:
The controlled-release implants are placed in the tumor bed during surgery, establishing preliminary therapeutic action before residual cancer cells can proliferate. The sustained-release mechanism ensures continuous delivery of multiple agents over an extended period, preventing the development of resistance and maintaining efficacy throughout the treatment duration.
3Reliability
If multiple therapeutic agents are combined to overcome signaling redundancies, then treatment efficacy improves, but formulation complexity increases
Solution Approach 1:
The biodegradable polymer matrix serves as a universal delivery platform that can accommodate multiple therapeutic agents with different physicochemical properties. The single formulation system provides controlled-release functionality, combines multiple mechanisms of action, and simplifies administration compared to separate therapies, thereby managing complexity while maintaining enhanced efficacy.
4Reliability
If surgical resection is performed with close margins, then complete tumor removal is achieved, but the risk of recurrence increases due to residual cancer cells
Solution Approach 1:
The controlled-release implants are placed in the tumor bed during surgery, establishing preliminary therapeutic action before residual cancer cells can proliferate. This immediate local treatment of the tumor bed eliminates or controls any remaining malignant cells at the resection site, preventing recurrence while maintaining complete surgical removal.
Data Source
AI summary
The present disclosure is directed to formulations and methods for treatment of disease such as chemoprevention of cancer, for example oral squamous cell carcinoma (OSCC), and for methods of preparing the formulations. Further, the disclosure relates to local administration in slow release dosage forms for treatment of disease. The extended-release formulations are comprised of biodegradable polymeric implants (for example millicylinders and microspheres as well as in situ forming gels) and therapeutic agents selected from an anti-interleukin 6 agent, a synthetic vitamin A analogue and/or metabolite, and/or an estradiol metabolite for the local delivery of therapeutic agents to a site where a cancer has been previously excised or to prevent progression of a precancerous lesion.